Equillium | Investor Presentation Deck | 32 slides

Equillium · 2023-12
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 2
No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.

Deck intelligence map

3
coverage by narrative range · generated from this deck JSON

Slide inventory

32
every slide · same image gating as the playbook
01
Slide 1
front_matter
03
The slide uses a hub-and-spoke diagram to centralize the company brand around key investment pillars.summarize
04
The slide uses a Gantt-style visualization to show clinical trial phases for different drug candidates.plan_implementation
05
This is a section divider or introductory slide for the product solution.present_solution
Open slide detailBeat · Solution (Provide relief)
06
The slide details a specific corporate partnership agreement.other
Open slide detailBeat · Solution (Provide relief)
07
The slide uses a side-by-side comparison structure to detail the status and upcoming milestones for two distinct clinical programs.show_traction
Open slide detailBeat · Solution (Provide relief)
08
transition
Open slide detailBeat · Solution (Provide relief)
09
Includes a diagram illustrating cytokine-receptor binding and downstream signaling.establish_context
Open slide detailBeat · Solution (Provide relief)
10
The slide uses a visual comparison to frame the problem of current therapeutic limitations.frame_problem
Open slide detailBeat · Problem (Identify pain)
11
The diagram uses a hub-and-spoke model to show how various scientific disciplines feed into the central 'Drug Products' core.present_solution
Open slide detailBeat · Solution (Provide relief)
12
The slide highlights the structural commonality of the γC receptor across multiple cytokines, positioning it as a therapeutic target.present_solution
Open slide detailBeat · Solution (Provide relief)
13
The slide uses a structural biology approach to explain the mechanism of action for their therapeutic platform.present_solution
Open slide detailBeat · Solution (Provide relief)
14
The slide uses a biological process diagram to illustrate how the inhibitor prevents the dimerization of private receptors with the shared receptor.present_solution
Open slide detailBeat · Solution (Provide relief)
15
The slide uses a visual comparison framework to illustrate the mechanism of action and therapeutic benefits.present_solution
Open slide detailBeat · Solution (Provide relief)
16
transition
Open slide detailBeat · Solution (Provide relief)
17
The slide uses a four-column structure to explain the target, molecular nature, preclinical results, and clinical status.present_solution
Open slide detailBeat · Solution (Provide relief)
18
The slide uses a column-based layout to compare four distinct medical conditions, each with specific patient counts and development milestones.size_opportunity
Open slide detailBeat · Solution (Provide relief)
19
The slide uses Western blot data to visually demonstrate the efficacy of EQ101 compared to a standard JAK inhibitor.present_solution
Open slide detailBeat · Solution (Provide relief)
20
Includes before/after patient photos and comparative data against Mogamulizumab.show_traction
Open slide detailBeat · Solution (Provide relief)
21
show_traction
Open slide detailBeat · Solution (Provide relief)Loop · Quick Win Big Bet
22
The slide uses a circular process diagram to show the feedback loop of cytokines and immune cells leading to hair loss.present_solution
Open slide detailBeat · Solution (Provide relief)
23
Includes visual longitudinal data (photos) and quantitative bar chart data.show_traction
Open slide detailBeat · Solution (Provide relief)
24
The slide compares two different drugs (baricitinib and deuruxolitinib) using their respective clinical trial data (BRAVE AA1 and THRIVE AA1).compare_peers
25
Includes a blackbox warning text block as a competitive/safety barrier context.frame_problem
Open slide detailBeat · Agitate (Make it worse)Loop · Cost Of Inaction
26
Includes a timeline diagram for the study phases and a target product profile comparison.present_framework
27
transition
29
The slide uses a Gantt-style timeline to show the duration of IP protection and exclusivity for various therapeutic assets.plan_implementation
30
Includes a disclaimer regarding the source of financial data (Form 10-Q).analyze_data
31
The slide uses a simple list-based timeline format.plan_implementation
32
state_next_steps